Short Interest in Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Increases By 93.4%

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 827,221 shares, an increase of 93.4% from the March 15th total of 427,713 shares. Based on an average daily volume of 335,772 shares, the days-to-cover ratio is presently 2.5 days. Approximately 1.5% of the shares of the company are sold short.

Wall Street Analyst Weigh In

DMRA has been the topic of a number of research analyst reports. Lifesci Capital upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Leerink Partners initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, January 7th. They set an “outperform” rating and a $46.00 target price for the company. Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price target for the company. Guggenheim reiterated a “buy” rating and issued a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.25.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA traded up $1.21 during mid-day trading on Tuesday, hitting $27.64. The company’s stock had a trading volume of 108,974 shares, compared to its average volume of 233,865. Damora Therapeutics, Inc. Common Stock has a one year low of $2.35 and a one year high of $38.33. The firm has a market capitalization of $1.67 billion, a PE ratio of -2.28 and a beta of 1.59. The stock’s 50-day moving average is $26.79 and its two-hundred day moving average is $21.60.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several hedge funds have recently modified their holdings of DMRA. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $76,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $49,000. Connective Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $100,000. Sigma Planning Corp bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $334,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $266,000. 14.20% of the stock is owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.